Search research articles
Contact Us
Filters
Showing results (61-70 of 88) with videos related to
Page
of 9
Sort By:
British Journal of Cancer
|
April 28, 2022
Intrahepatic cholangiocarcinoma hidden within cancer of unknown primary
Alicia-Marie Conway, Georgina C Morris, Sarah Smith, et al.
Supportive Care in Cancer : Official Journal of the Multinational Association of Supportive Care in Cancer
|
January 17, 2024
Correction to: Evaluating a shared care pathway intervention for people receiving chemotherapy to reduce post‑treatment unplanned hospital presentations: a randomised controlled trial
Judith Fethney, Bora Kim, Chantale Boustany, et al.
Supportive Care in Cancer : Official Journal of the Multinational Association of Supportive Care in Cancer
|
January 3, 2024
Evaluating a shared care pathway intervention for people receiving chemotherapy to reduce post-treatment unplanned hospital presentations: a randomised controlled trial
Judith Fethney, Bora Kim, Chantale Boustany, et al.
Cancer Medicine
|
February 26, 2024
Biomarkers of systemic inflammation provide additional prognostic stratification in cancers of unknown primary
Svenja Harvey, Mark Stares, Julie-Anne Scott, et al.
Cancer Chemotherapy and Pharmacology
|
March 25, 2011
A novel method for quantification of gemcitabine and its metabolites 2',2'-difluorodeoxyuridine and gemcitabine triphosphate in tumour tissue by LC-MS/MS: comparison with (19)F NMR spectroscopy
Tashinga E Bapiro, Frances M Richards, Mae A Goldgraben, et al.
British Journal of Cancer
|
August 3, 2023
A Phase Ib/II study of IGF-neutralising antibody xentuzumab with enzalutamide in metastatic castration-resistant prostate cancer
Valentine M Macaulay, Simon Lord, Syed Hussain, et al.
British Journal of Cancer
|
June 4, 2026
A first-in-human, open-label multicentre Phase 1 study of the orally administered E7386 in patients with selected advanced neoplasms
T R Jeffry Evans, Natalie Cook, Anthony El-Khoueiry, et al.
NPJ Genomic Medicine
|
June 29, 2018
Signaling pathway screening platforms are an efficient approach to identify therapeutic targets in cancers that lack known driver mutations: a case report for a cancer of unknown primary origin
Pedro Torres-Ayuso, Sudhakar Sahoo, Garry Ashton, et al.
Eclinicalmedicine
|
April 19, 2021
First-in-human study of the safety, pharmacokinetics, and pharmacodynamics of first-in-class fatty acid synthase inhibitor TVB-2640 alone and with a taxane in advanced tumors
Gerald Falchook, Jeffrey Infante, Hendrik-Tobias Arkenau, et al.
The Lancet. Oncology
|
December 17, 2013
Docetaxel versus active symptom control for refractory oesophagogastric adenocarcinoma (COUGAR-02): an open-label, phase 3 randomised controlled trial
Hugo E R Ford, Andrea Marshall, John A Bridgewater, et al.
Page
of 9
Search research articles
Search
Showing results (61-70 of 88) with videos related to
Sort By:
Page
of 9
British Journal of Cancer
|
April 28, 2022
Intrahepatic cholangiocarcinoma hidden within cancer of unknown primary
Alicia-Marie Conway, Georgina C Morris, Sarah Smith, et al.
Supportive Care in Cancer : Official Journal of the Multinational Association of Supportive Care in Cancer
|
January 17, 2024
Correction to: Evaluating a shared care pathway intervention for people receiving chemotherapy to reduce post‑treatment unplanned hospital presentations: a randomised controlled trial
Judith Fethney, Bora Kim, Chantale Boustany, et al.
Supportive Care in Cancer : Official Journal of the Multinational Association of Supportive Care in Cancer
|
January 3, 2024
Evaluating a shared care pathway intervention for people receiving chemotherapy to reduce post-treatment unplanned hospital presentations: a randomised controlled trial
Judith Fethney, Bora Kim, Chantale Boustany, et al.
Cancer Medicine
|
February 26, 2024
Biomarkers of systemic inflammation provide additional prognostic stratification in cancers of unknown primary
Svenja Harvey, Mark Stares, Julie-Anne Scott, et al.
Cancer Chemotherapy and Pharmacology
|
March 25, 2011
A novel method for quantification of gemcitabine and its metabolites 2',2'-difluorodeoxyuridine and gemcitabine triphosphate in tumour tissue by LC-MS/MS: comparison with (19)F NMR spectroscopy
Tashinga E Bapiro, Frances M Richards, Mae A Goldgraben, et al.
British Journal of Cancer
|
August 3, 2023
A Phase Ib/II study of IGF-neutralising antibody xentuzumab with enzalutamide in metastatic castration-resistant prostate cancer
Valentine M Macaulay, Simon Lord, Syed Hussain, et al.
British Journal of Cancer
|
June 4, 2026
A first-in-human, open-label multicentre Phase 1 study of the orally administered E7386 in patients with selected advanced neoplasms
T R Jeffry Evans, Natalie Cook, Anthony El-Khoueiry, et al.
NPJ Genomic Medicine
|
June 29, 2018
Signaling pathway screening platforms are an efficient approach to identify therapeutic targets in cancers that lack known driver mutations: a case report for a cancer of unknown primary origin
Pedro Torres-Ayuso, Sudhakar Sahoo, Garry Ashton, et al.
Eclinicalmedicine
|
April 19, 2021
First-in-human study of the safety, pharmacokinetics, and pharmacodynamics of first-in-class fatty acid synthase inhibitor TVB-2640 alone and with a taxane in advanced tumors
Gerald Falchook, Jeffrey Infante, Hendrik-Tobias Arkenau, et al.
The Lancet. Oncology
|
December 17, 2013
Docetaxel versus active symptom control for refractory oesophagogastric adenocarcinoma (COUGAR-02): an open-label, phase 3 randomised controlled trial
Hugo E R Ford, Andrea Marshall, John A Bridgewater, et al.
Page
of 9